| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Not applicable for the deuterated standard. Bilastine (parent) is a selective, non‑sedating, second‑generation histamine H1 receptor antagonist. Bilastine binds to the H1 receptor with high affinity (Ki ~ 4 nM) and has no significant affinity for cholinergic, dopaminergic, serotonergic, or adrenergic receptors. Its selectivity for peripheral H1 receptors over CNS receptors (due to P‑glycoprotein efflux) results in a low incidence of sedation.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
Not applicable. Bilastine-d6 itself is not used for measuring pharmacological activity. Unlabeled bilastine is a potent and selective H1 antagonist, inhibiting histamine‑induced bronchoconstriction and vascular permeability. In vitro, bilastine inhibits histamine‑induced calcium mobilization in H1‑expressing CHO cells with an IC50 of approximately 5‑10 nM. It has no significant activity at the hERG channel at therapeutic concentrations. |
| ln Vivo |
Not applicable. Bilastine-d6 is an analytical standard and is not used for in vivo activity assays. The parent compound bilastine is used clinically for the treatment of allergic rhinitis and chronic idiopathic urticaria. It is rapidly absorbed, has a long duration of action (24 h), and is well‑tolerated. The labeled standard is used in ADME studies to quantify bilastine levels.
|
| Enzyme Assay |
For analytical method development, Bilastine-d6 is used as an internal standard. A stock solution is prepared in methanol or acetonitrile at 1 mg/mL. Calibration standards are prepared by spiking blank biological matrix (e.g., plasma, urine) with known concentrations of unlabeled bilastine (0.1‑1000 ng/mL) and a fixed concentration of Bilastine-d6 (10‑100 ng/mL). For protein precipitation, 3‑5 volumes of acetonitrile containing the internal standard are added. After centrifugation, the supernatant is evaporated and reconstituted in mobile phase (0.1% formic acid in water/methanol). Analysis is performed by LC‑MS/MS in MRM mode, monitoring transitions: for bilastine, m/z 464.3 → 260.3 (or 464 → 246); for bilastine-d6 (butoxy‑d6), m/z 470.3 → 266.3 (or 470 → 252). The peak area ratio (analyte/IS) is plotted against the nominal concentration to generate a calibration curve.
|
| Cell Assay |
Bilastine-d6 is not used in cellular activity assays. In research settings, the parent compound bilastine can be used to study H1 receptor antagonism. CHO cells expressing the H1 receptor are loaded with Fluo‑4 AM, pre‑incubated with bilastine (0.1‑1000 nM), and then stimulated with histamine (EC80). Fluorescence is measured. The IC50 for inhibition is ~5 nM. However, the deuterated analog is not used in such assays.
|
| Animal Protocol |
Bilastine-d6 is used in pharmacokinetic (PK) and bioequivalence studies of bilastine in animal models and humans. Animals (e.g., male Sprague‑Dawley rats, 200‑300 g) are administered an oral dose of bilastine (5‑20 mg/kg for rats, 20 mg for humans). Blood samples are collected at predetermined time points (0, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24 h). Plasma is separated, and the concentration of bilastine is measured by LC‑MS/MS using Bilastine-d6 as an internal standard. Pharmacokinetic parameters (Cmax, Tmax, AUC, t½, clearance, Vd, oral bioavailability) are calculated. In rats, bilastine has a half‑life of 2‑4 hours, and in humans, the half‑life is 12‑16 hours. The deuterium label does not alter metabolism or PK.
|
| ADME/Pharmacokinetics |
Bilastine-d6 (MW 469.65, C28H31D6N3O3) is a stable isotope‑labeled compound with 99 atom% deuterium. It has the same chemical and physical properties as unlabeled bilastine. Bilastine is a non‑sedating antihistamine that is well absorbed orally (bioavailability ~60%). It is not metabolized by CYP450 enzymes; it is excreted unchanged in urine (33%) and feces (50%). The compound is a substrate for P‑glycoprotein, which limits its entry into the CNS. Plasma protein binding is high (~95%). The deuterated analog is used as an internal standard.
|
| Toxicity/Toxicokinetics |
Bilastine-d6 is non‑toxic at the concentrations used as an internal standard (ng/mL levels). Unlabeled bilastine is a clinically approved drug with a well‑established safety profile; adverse effects include headache, drowsiness, and dry mouth (less frequent than with first‑generation antihistamines). The labeled analog is not for human consumption. Storage: powder at -20degC for 3 years, protected from light.
|
| References |
|
| Additional Infomation |
Bilastine-d6 (CAS 1215358-58-9) is a stable isotope‑labeled internal standard for LC‑MS/MS quantification of bilastine, a second‑generation H1 antihistamine used for allergic rhinitis and urticaria. The labeled analog is for research and analytical purposes only. Storage: at -20degC.
|
| Molecular Formula |
C28H31D6N3O3
|
|---|---|
| Molecular Weight |
469.65
|
| Exact Mass |
469.321
|
| CAS # |
1215358-58-9
|
| Related CAS # |
Bilastine;202189-78-4
|
| PubChem CID |
57369243
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
632.6±55.0 °C at 760 mmHg
|
| Flash Point |
336.4±31.5 °C
|
| Vapour Pressure |
0.0±2.0 mmHg at 25°C
|
| Index of Refraction |
1.594
|
| LogP |
5.06
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
34
|
| Complexity |
649
|
| Defined Atom Stereocenter Count |
0
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1292 mL | 10.6462 mL | 21.2925 mL | |
| 5 mM | 0.4258 mL | 2.1292 mL | 4.2585 mL | |
| 10 mM | 0.2129 mL | 1.0646 mL | 2.1292 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
